

Hypertrophic cardiomyopathy detection with artificial intelligence electrocardiography in international cohorts: an external validation study

Konstantinos C. Siontis ^{1,*}, Mikolaj A. Wiczorek², Maren Maanja^{1,3}, David O. Hodge², Hyung-Kwan Kim ^{4,5}, Hyun-Jung Lee^{4,5}, Heesun Lee^{4,6}, Jaehyun Lim^{4,5}, Chan Soon Park^{4,5}, Rina Ariga⁷, Betty Raman ⁷, Masliza Mahmud ⁷, Hugh Watkins ⁷, Stefan Neubauer ⁷, Stephan Windecker ⁸, George C.M. Siontis⁸, Bernard J. Gersh¹, Michael J. Ackerman ^{1,9,10}, Zachi I. Attia¹, Paul A. Friedman ¹, and Peter A. Noseworthy¹

¹Department of Cardiovascular Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; ²Department of Quantitative Health Sciences, Mayo Clinic, 4500 San Pablo Rd S, Jacksonville, FL 32224, USA; ³Department of Clinical Physiology, Karolinska University Hospital, Karolinska Institutet, Eugeniavägen 3, Solna, Sweden; ⁴Department of Internal Medicine, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul, Republic of Korea; ⁵Division of Cardiology, Cardiovascular Center, Seoul National University Hospital, 103 Daehak-ro, Jongno-gu, Seoul, Republic of Korea; ⁶Healthcare System Gangnam Center, Seoul National University Hospital, 152 Tehran Street, Gangnam-gu, Seoul, Republic of Korea; ⁷Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK; ⁸Department of Cardiology, Bern University Hospital, University of Bern, Freiburgstrasse 20, 3010 Bern, Switzerland; ⁹Division of Pediatric Cardiology, Department of Pediatric and Adolescent Medicine, Windland Smith Rice Genetic Heart Rhythm Clinic, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; and ¹⁰Department of Molecular Pharmacology and Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA

Received 2 November 2023; revised 9 March 2024; accepted 11 March 2024; online publish-ahead-of-print 15 April 2024

Aims

Recently, deep learning artificial intelligence (AI) models have been trained to detect cardiovascular conditions, including hypertrophic cardiomyopathy (HCM), from the 12-lead electrocardiogram (ECG). In this external validation study, we sought to assess the performance of an AI-ECG algorithm for detecting HCM in diverse international cohorts.

Methods and results

A convolutional neural network-based AI-ECG algorithm was developed previously in a single-centre North American HCM cohort (Mayo Clinic). This algorithm was applied to the raw 12-lead ECG data of patients with HCM and non-HCM controls from three external cohorts (Bern, Switzerland; Oxford, UK; and Seoul, South Korea). The algorithm's ability to distinguish HCM vs. non-HCM status from the ECG alone was examined. A total of 773 patients with HCM and 3867 non-HCM controls were included across three sites in the merged external validation cohort. The HCM study sample comprised 54.6% East Asian, 43.2% White, and 2.2% Black patients. Median AI-ECG probabilities of HCM were 85% for patients with HCM and 0.3% for controls ($P < 0.001$). Overall, the AI-ECG algorithm had an area under the receiver operating characteristic curve (AUC) of 0.922 [95% confidence interval (CI) 0.910–0.934], with diagnostic accuracy 86.9%, sensitivity 82.8%, and specificity 87.7% for HCM detection. In age- and sex-matched analysis (case–control ratio 1:2), the AUC was 0.921 (95% CI 0.909–0.934) with accuracy 88.5%, sensitivity 82.8%, and specificity 90.4%.


* Corresponding author. Tel: +1 507 255 1051, Fax: +1 507 255 2550, Email: siontis.konstantinos@mayo.edu

© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Conclusion

The AI-ECG algorithm determined HCM status from the 12-lead ECG with high accuracy in diverse international cohorts, providing evidence for external validity. The value of this algorithm in improving HCM detection in clinical practice and screening settings requires prospective evaluation.

Graphical Abstract**Keywords**

Hypertrophic cardiomyopathy • Electrocardiogram • Artificial intelligence

Introduction

The diagnosis of hypertrophic cardiomyopathy (HCM), one of the most common genetic heart diseases predisposing to sudden cardiac death (SCD), relies on clinical assessment and cardiac imaging, namely echocardiography and cardiac magnetic resonance.¹ However, these modalities are not always readily available and can only be interpreted by clinicians with expertise. Hypertrophic cardiomyopathy may also remain asymptomatic for a long time or cause non-specific symptoms that are often unsuspected and undiagnosed in early stages.² Prompt diagnosis of HCM can lead to appropriate disease surveillance, family screening, and timely implementation of outcome-modifying interventions, including implantable cardioverter-defibrillators when indicated.

The 12-lead electrocardiogram (ECG) is an integral test in the evaluation of patients with cardiovascular symptoms and can offer important insights in patients with known or suspected HCM.³ Yet, ECG interpretation requires expertise and there are no pathognomonic ECG features of HCM. The cardinal ECG features of HCM, including left ventricular hypertrophy (LVH) by voltage criteria, repolarization

abnormalities, and Q waves may be observed in other conditions such as hypertensive heart disease, aortic stenosis, and in athlete's heart.^{4,5} Furthermore, the ECG can be normal in ~5–10% of patients with HCM.⁶

Deep learning artificial intelligence (AI) applications on the ECG have great potential to detect occult cardiovascular disease.⁷ An algorithm based on convolutional neural network (CNN) architecture (AI-ECG) was recently developed to detect HCM from the standard 12-lead ECG alone without any additional input of patient demographic or clinical information.⁸ This AI-ECG algorithm performed well in patients with common HCM 'mimics' and in patients with a normal ECG, suggesting that it can help extend clinicians' ability to suspect HCM from the routine ECG, followed by confirmatory imaging studies. This algorithm was trained and internally tested in a population from a tertiary institution in North America (Mayo Clinic) and validated subsequently in a paediatric/adolescent population of HCM from the same institution,⁹ but it has not yet undergone extensive external validation. Herein, we sought to externally evaluate the performance of this AI-ECG algorithm in diverse international cohorts of patients undergoing ECG in clinical practice.

Methods

Study design

The study design was in adherence to the TRIPOD statement.¹⁰ This retrospective case–control study consisted of cohorts from geographically diverse tertiary care institutions providing care to patients with HCM. The participating centres and subject enrolment periods in each centre were as follows: the University of Bern, Switzerland (2014–20); Oxford University, UK (2013–21); and Seoul National University, South Korea (2007–20). Each centre contributed data on consecutive adult patients with HCM who had available research authorization. Patients with HCM were eligible for inclusion if they had a definite HCM diagnosis by standard European Society of Cardiology (ESC) and American College of Cardiology (ACC) / American Heart Association (AHA) criteria^{1,11} and had at least one 12-lead ECG available in digital format. Specifically, HCM was defined as LVH ≥ 15 mm based on echocardiography or cardiac magnetic resonance imaging in the absence of other causes of hypertrophy. In those with family history of HCM or known pathogenic HCM mutation, left ventricular (LV) wall thickness ≥ 13 mm was sufficient for the definition of HCM. This aligns with the diagnostic approach of HCM in the algorithm derivation cohort.⁸ All HCM diagnoses were adjudicated with a case-by-case review by cardiologists at the participating institutions utilizing available clinical and imaging information in the patient's record. The time of HCM diagnosis coincided with the cardiologist's impression that a patient met diagnostic criteria for HCM. Readily available control groups without HCM with a 12-lead ECG performed as part of clinical practice at each institution were also included (not all-inclusive of all patients with non-HCM evaluated at the institutions during the study period). The inclusion of control subjects relied on the availability of research authorization and digital ECG files for each patient rather than specific patient characteristics or a pre-defined case–control ratio.

Data collection

Standard, 10 s, 12-lead ECGs from cases and controls were acquired in the supine position at a sampling rate of 500 Hz ECGs in all participating centres, and ECG files in csv or xml format were transferred securely to the co-ordinating team at Mayo Clinic for AI-ECG analysis. One ECG per patient was used in this study. For patients with HCM with multiple available ECGs, the first ECG after the clinical diagnosis of HCM was included. Similarly, for control patients with multiple available ECGs, their first available ECG was included. There were no restrictions for ECG inclusion by patient age, year of HCM diagnosis, prior myectomy, and presence of ventricular pacing, bundle branch block (BBB), or other ECG abnormality. Notably, for algorithm development,⁸ ECGs with the presence of ventricular pacing or left bundle branch block (LBBB) were excluded, while these exclusions did not apply in the current study as we wanted to adopt an all-inclusive validation approach. All ECGs were analysed as acquired without selection for tracing quality or any pre-processing. Electrocardiogram machine manufacturers were Schiller in Bern, Burdick in Oxford, and GE in Seoul.

Each ECG tracing in the HCM and control groups was reviewed by a single reviewer (cardiologist) blinded to HCM vs. control status in order to document the following ECG features using pre-defined criteria: normal vs. abnormal ECG, atrial fibrillation or flutter (AF), LVH present (per Sokolow–Lyon criteria), ventricular pacing, right bundle branch block (RBBB), LBBB, inferior or lateral T-wave inversions (TWIs), pathologic Q waves, and presence of artefact that could interfere with ECG interpretation according to the reviewer's opinion.

Artificial intelligence electrocardiogram model

The Mayo Clinic AI-ECG model for HCM detection has been described previously.⁸ In brief, 3060 patients with a validated HCM diagnosis were age- and sex-matched to 63 941 non-HCM controls and split into training, validation, and testing groups using a 70:10:20 ratio. Digitally stored, 10-s, 12-lead ECGs acquired with a GE-Marquette machine in the supine position were converted to a 12×5000 matrix, and a CNN using the Keras framework with a TensorFlow backend

(Google, Mountain View, CA, USA) and Python (Python Software Foundation, Beaverton, OR, USA) was applied. In the matrix, the first dimension is spatial and the second dimension is temporal. Convolutions occurred within each lead and across different leads of the 12-lead recording. After initial training, the model was fine-tuned in the internal validation data set. The optimal probability threshold for binary classification of the AI output as indicating HCM vs. no HCM diagnosis was determined to be 11% (the best combination of sensitivity and specificity or Youden's index) based on the validation dataset receiver operating characteristic (ROC) curve in that population. The test was considered positive (i.e. AI-ECG indicates that any given ECG belongs to a patient with HCM) when the CNN output probability value was $>11\%$. The optimal model from the training and validation steps was then tested in a separate subset of the dataset deriving an area under the ROC curve (AUC) of 0.96 with sensitivity 87% and specificity 90% for detecting HCM.

Statistical analyses

We report demographic and clinical characteristics of the HCM and control groups in the merged data set combining all three cohorts and in each cohort separately. Categorical variables are reported as absolute numbers and percentages, and continuous variables are reported as median and inter-quartile range (IQR). Two-tailed *P*-values <0.05 were considered statistically significant. Analyses were conducted using R Statistical Software (version 4.0.3; R Foundation for Statistical Computing, Vienna, Austria). The Institutional Review Boards of Mayo Clinic and of the participating centres approved the study.

The primary analysis was designed to determine the ability of the AI-ECG model to distinguish patients with HCM from non-HCM controls using the 12-lead ECG in the merged cohort (all three sites). In the secondary analysis, cohort-specific diagnostic performance metrics were also derived. Outputs of the AI-ECG model were generated for each HCM and non-HCM ECG representing the AI-ECG-predicted probability for that ECG belonging to a patient with HCM. Importantly, the AI model was applied to the ECG data as initially developed without any further adjustment or refinement and without any demographic or clinical information as model inputs. Summaries of the AI-ECG probabilities of HCM were reported in HCM and control subjects in the merged cohort and in each cohort separately. In order to determine true and false positive and negative detections of cases and controls by the AI-ECG algorithm, we utilized the original optimal probability threshold (11%) established during algorithm derivation, defined as the optimal balance between sensitivity and specificity (Youden's index).⁸ Using the HCM status label provided by each participating centre as reference, we calculated accuracy, sensitivity, and specificity. In the secondary analyses, overall and cohort-specific optimal probability thresholds of AI-ECG outputs were also determined in order to calculate these metrics. Receiver operating characteristic curves were created, and the AUCs with 95% confidence intervals (CIs) were estimated. In the merged cohort, we also calculated the performance characteristics in subgroups defined by age, sex, ECG, and HCM characteristics. DeLong's test was used to test for differences in the AUCs between subgroups. We also assessed algorithm diagnostic performance in an age- and sex-based nearest-neighbour matched cohort using a 1:2 ratio of cases and controls. A matching calliper of ± 5 years was used for age.

Results

Cohort characteristics

A total of 773 patients with HCM and 3867 non-HCM controls from routine clinical practice were included across sites. Overall, the median age of patients with HCM and patients with non-HCM was 56 and 65.4 years, respectively ($P < 0.001$). The proportion of women in the HCM and non-HCM groups was 30.7 and 36.8%, respectively ($P = 0.001$). The total HCM cohort consisted of 54.6% East Asian, 43.2% White, and 2.2% Black patients. The prevalence of obstructive HCM was 15.7%, while apical HCM comprised 21.9% of cases with

Table 1 Hypertrophic cardiomyopathy cohort characteristics

HCM cases	Overall n = 773	Bern n = 66	Oxford n = 304	Seoul n = 403
Sex				
Male	536 (69.3%)	36 (54.5%)	236 (77.6%)	264 (65.5%)
Female	237 (30.7%)	30 (45.5%)	68 (22.4%)	139 (34.5%)
Age (years)	56.0 (47.0, 65.0)	60.2 (49.4, 70.7)	52.0 (42.0, 59.0)	59.0 (51.5, 68.0)
Age (years)				
<40	105 (13.6%)	9 (13.6%)	64 (21.1%)	32 (7.9%)
40–59	366 (47.3%)	23 (34.8%)	170 (55.9%)	173 (42.9%)
60–79	292 (37.8%)	27 (40.9%)	69 (22.7%)	196 (48.6%)
≥80	10 (1.3%)	7 (10.6%)	1 (0.3%)	2 (0.5%)
Race				
East Asian	422 (54.6%)	1 (1.5%)	18 (5.9%)	403 (100.0%)
Black	17 (2.2%)	0 (0.0%)	17 (5.6%)	0 (0.0%)
White	334 (43.2%)	65 (98.5%)	269 (88.5%)	0 (0.0%)
Coronary artery disease	99 (12.8%)	19 (28.8%)	5 (1.6%)	75 (18.6%)
Atrial fibrillation	161 (20.8%)	37 (56.1%)	34 (11.2%)	90 (22.3%)
Cerebrovascular event	98 (12.7%)	34 (51.5%)	9 (3.0%)	55 (13.6%)
Diabetes	108 (14.0%)	11 (16.7%)	13 (4.3%)	84 (20.8%)
Hypertension	268 (34.7%)	35 (53.0%)	55 (18.1%)	178 (44.2%)
Sudden cardiac arrest	27 (3.5%)	9 (13.6%)	15 (4.9%)	3 (0.7%)
Implantable cardioverter–defibrillator ^a	47 (6.1%)	15 (22.7%)	23 (7.6%)	9 (2.2%)
Obstructive phenotype	121 (15.7%)	37 (56.9%)	43 (14.1%)	41 (10.2%)
Apical HCM	169 (21.9%)	4 (6.1%)	21 (6.9%)	144 (35.7%)
Family history of HCM	189 (24.5%)	29 (44.6%)	117 (38.5%)	43 (10.7%)
LVEF (%)	65.0 (60.0, 70.0)	65.0 (55.0, 65.0)	67.0 (61.7, 73.9)	64.0 (60.0, 68.0)
LVEF <50%	23 (3%)	7 (10.6%)	9 (3%)	7 (1.7%)
Resting LVOT gradient (mmHg)	6.3 (4.2, 13.0)	20.5 (10.0, 67.5)	7.8 (5.0, 15.0)	5.4 (3.8, 9.0)
Maximum wall thickness (mm)	19.0 (16.1, 22.0)	20.0 (17.0, 23.0)	20.0 (16.8, 23.2)	18.0 (16.0, 21.0)
Genetic testing performed	405 (52.4%)	17 (25.8%)	304 (100%)	84 (20.8%)
Genetic testing positive	194 (25.1%)	12 (18.2%)	145 (47.7%)	37 (9.2%)
Controls	n = 3867	n = 3350	n = 117	n = 400
Sex				
Male	2443 (63.2%)	2157 (64.4%)	74 (63.2%)	212 (53.0%)
Female	1424 (36.8%)	1193 (35.6%)	43 (36.8%)	188 (47.0%)
Age (years)	65.4 (54.2, 75.0)	67.5 (57.0, 76.3)	47.0 (30.0, 61.0)	53.0 (46.0, 60.0)
Age (years)				
<40	301 (7.8%)	223 (6.7%)	46 (39.3%)	32 (8.0%)
40–59	1059 (27.4%)	757 (22.6%)	38 (32.5%)	264 (66.0%)
60–79	1842 (47.6%)	1711 (51.1%)	31 (26.5%)	100 (25.0%)
≥80	665 (17.2%)	659 (19.7%)	2 (1.7%)	4 (1.0%)

Data shown as absolute counts (%) or medians (inter-quartile range).

HCM, hypertrophic cardiomyopathy; LVEF, left ventricular ejection fraction; LVOT, left ventricular outflow tract.

^aPrior or future implantable cardioverter–defibrillator implantation.

most of them originating from the Seoul cohort. Among patients with HCM, median ejection fraction, maximum wall thickness, and LV outflow tract gradient were 65% (IQR 60–70%), 19 mm (IQR 16.1–22 mm), and 6.3 mmHg (IQR 4.2–13 mmHg), respectively. Genetic testing was performed in 405 patients with HCM, and pathogenic/likely pathogenic variants in a gene for sarcomeric HCM were identified in 194 (48%). Detailed characteristics of the HCM cohorts from each participating site are shown in [Table 1](#).

Artificial intelligence electrocardiogram analysis for hypertrophic cardiomyopathy detection

Across all cohorts, median (IQR) AI-ECG probabilities of HCM were 85% (37–98%) for patients with HCM and 0.3% (0.05–2%) for controls ($P < 0.001$) ([Figures 1](#) and [2](#)). Among patients with HCM, AI-ECG probabilities were higher for apical compared with non-apical HCM [94%




Figure 1 Distribution of artificial intelligence algorithm-derived probabilities of hypertrophic cardiomyopathy in cases and controls as percentages of the total sample.

(IQR 75–99%) vs. 79% (IQR 24–97%), $P < 0.001$], but there were no differences for obstructive vs. non-obstructive HCM [90% (IQR 44–98%) vs. 85% (IQR 35–97%), $P = 0.45$], those with positive vs. negative genetic testing for sarcomeric mutations [73% (IQR 15–96%) vs. 86% (IQR 22–97%), $P = 0.16$], and those with vs. without hypertension [83% (IQR 28–97%) vs. 86% (IQR 42–98%), $P = 0.41$].

The AI-ECG model had an AUC of 0.922 (95% CI 0.910–0.934) for HCM detection in the combined study cohort. Applying the optimal AI-ECG probability threshold as defined in the derivation cohort (equal to 11%),⁸ accuracy, sensitivity, and specificity were 86.9, 82.8, and 87.7%, respectively. In the secondary analysis, the optimal AI-ECG HCM probability threshold based on the Youden index was 18% in the combined cohort. Applying this diagnostic threshold, the AI-ECG model had an accuracy of 89.2%, a sensitivity of 80.6%, and a specificity of 90.9%. Detailed performance characteristics and ROC curves are shown in *Table 2* and *Figure 3*, respectively. In another secondary analysis excluding 15 patients with HCM and 104 control patients with prior septal reduction therapy or ventricular pacing, results were very similar (AUC 0.922, accuracy 86.8%, sensitivity 83%, and specificity 87.6%).

In subgroup analyses, AI-ECG model performance was overall better in females compared with males with respective AUCs 0.94 (95% CI 0.92–0.96) and 0.91 (95% CI 0.90–0.93) ($P = 0.01$) (*Figure 4*). Also, AUC and sensitivity were higher for patients with apical vs. non-apical HCM, but there were no differences between other examined subgroups (*Figure 5*).

In an age- and sex-matched analysis (case–control ratio 1:2), a total of 773 patients with HCM and 1546 control patients were included. In this cohort, the AUC of the AI-ECG model was 0.921 (95% CI 0.909–0.934) with accuracy 88.5%, sensitivity 82.8%, and specificity 90.4%, similar to the performance in the non-matched population.

Cohort-specific artificial intelligence electrocardiogram results

The median (IQR) AI-ECG probabilities of HCM for patients with HCM were 29% (2–88%) in the Bern cohort, 72% (10–95%) in the Oxford cohort, and 91% (62–99%) in the Seoul cohort. In comparison, AI-ECG probabilities of HCM for control subjects were 0.2% (0.04–0.2%), 0.2% (0.04–0.1%), and 0.4% (0.1–3%) in the same cohorts, respectively (*Figure 2*). In site-specific analyses, the AUCs ranged from 0.835 to 0.948. Using the original optimal probability threshold (equal to 11%), sensitivity ranged from 62.1 to 93.1%, while specificity showed lower variation ranging from 86.8 to 90.6% across sites (*Table 2* and *Figure 3*).

Electrocardiogram morphology assessment

Compared with control patients, the HCM group had lower prevalences of normal ECGs and ventricular pacing and higher prevalences of RBBB, LVH, TWIs, and pathologic Q waves (*Table 3*). There were no statistically significant differences between the two groups in the frequency of AF, LBBB, or ECG tracing artefact. In subgroup analyses defined by these features (*Figure 4*), the AI-ECG algorithm demonstrated statistically superior performance for HCM detection among abnormal vs. normal ECGs (AUC 0.93 vs. 0.84, $P < 0.001$), ECGs with vs. without LVH (AUC 0.93 vs. 0.90, $P = 0.012$), and ECGs without vs. with artefact (AUC 0.93 vs. 0.82, $P = 0.022$). For ECGs with TWIs, there was a trend towards superior performance compared with ECGs without TWIs (AUC 0.91 vs. 0.88, $P = 0.053$). No differences in algorithm performance were noted according to the presence of atrial arrhythmia, ventricular pacing, LBBB, RBBB, or pathologic Q waves.




Figure 2 Cohort-specific artificial intelligence algorithm-derived probabilities of hypertrophic cardiomyopathy in (A) hypertrophic cardiomyopathy cases and (B) controls. The box plots show median, inter-quartile range, and max–min values of artificial intelligence scores. Optimal algorithm probability thresholds (based on the Youden index) for detecting hypertrophic cardiomyopathy status were as follows: combined cohort = 18%, Bern = 7%, Oxford = 4%, and Seoul = 18%. The optimal probability threshold in the algorithm’s derivation cohort from Mayo Clinic was 11%.


Table 2 Artificial intelligence electrocardiogram model performance metrics by site

Site	AUC	Optimal probability threshold	Accuracy	Sensitivity	Specificity
Overall	0.922 (0.910, 0.934)	0.11 ^a	86.9% (85.8%, 87.8%) 4030/4640	82.8% (79.9%, 85.4%) 640/773	87.7% (86.6%, 88.7%) 3390/3867
Bern	0.835 (0.782, 0.887)	0.18 ^b	89.2% (88.3%, 90.1%) 4139/4640	80.6% (77.6%, 83.3%) 623/773	90.9% (90.0%, 91.8%) 3516/3867
		0.11 ^a	87.2% (86.0%, 88.3%) 2978/3416	62.1% (49.3%, 73.8%) 41/66	87.7% (86.5%, 88.8%) 2937/3350
		0.07 ^b	83.3% (82.0%, 84.5%) 2844/3416	68.2% (55.6%, 79.1%) 45/66	83.6% (82.3%, 84.8%) 2799/3350
Oxford	0.900 (0.869, 0.931)	0.11 ^a	78.4% (74.1%, 82.2%) 330/421	73.7% (68.4%, 78.5%) 224/304	90.6% (83.8%, 95.2%) 106/117
Seoul	0.948 (0.933, 0.964)	0.04 ^b	84.6% (80.7%, 87.9%) 356/421	83.9% (79.3%, 87.8%) 255/304	86.3% (78.7%, 92.0%) 101/117
		0.11 ^a	89.9% (87.6%, 91.9%) 722/803	93.1% (90.1%, 95.3%) 375/403	86.8% (83.0%, 89.9%) 347/400
		0.18 ^b	90.4% (88.2%, 92.4%) 726/803	91.6% (88.4%, 94.1%) 369/403	89.2% (85.8%, 92.1%) 357/400

95% confidence intervals are shown in parentheses.

^aOptimal AI-ECG probability threshold as defined in the algorithm derivation cohort.

^bArtificial intelligence electrocardiogram probability threshold as optimized for each cohort using the Youden index method.



Discussion

We report one of the initial attempts for external validation of an AI-ECG algorithm for detecting HCM from the standard 12-lead ECG. The main findings of our study are as follows: (i) overall AI-ECG performance was favourable with an AUC of 0.92, a sensitivity of ~83%, and a specificity of approximately 88% in the merged cohort, with similar performance noted in an analysis using age and sex matching for cases and controls; (ii) AI-ECG diagnostic performance was good in all sites though site-level variations were present, particularly for sensitivity; (iii) AI-ECG performance was statistically superior in females and those with any ECG abnormality present, including also presence of ECG criteria for LVH; and (iv) ECG tracing artefact was significantly associated with lower AI-ECG algorithm performance, suggesting variability of the tracing quality may have at least partly contributed to the model performance variations across sites.

This study is one component of the validation efforts of the Mayo Clinic AI-ECG HCM algorithm, including a previous study in paediatric patients with HCM where the algorithm demonstrated excellent discrimination performance⁹ and an internal validation where the

algorithm was applied in tandem with clinical factors to optimize detection of new HCM cases in routine clinical practice.¹² External validation is essential to rigorous evaluation and ultimate adoption of diagnostic and prognostic AI-based tools.¹³ In this multicentre study compiling primary ECG data, an AI-ECG algorithm that was developed in a single-centre tertiary care North American cohort performed favourably in patients from geographically diverse institutions in Europe and Asia. This evidence of external validity suggests that the model can be generalized to populations with distinct differences compared with the development cohort. For example, the development cohort consisted of many patients with severe HCM phenotype referred for septal reduction therapies and a low prevalence of apical HCM (<10%).⁸ The current results demonstrate the validity of the AI-ECG algorithm in cohorts with a lower prevalence of obstructive HCM and a higher prevalence of apical HCM, though it is also noteworthy that AI-ECG-estimated probabilities were not significantly different in patients with obstructive and non-obstructive HCM phenotypes. Furthermore, the demonstration of excellent model performance in a predominantly Asian cohort from South Korea with an AUC of 0.95 is reassuring since only a tiny minority of patients in the derivation

Group	Fraction (%) with HCM	AUC	Sensitivity	Specificity		Odds Ratio	P-value
Sex							
Male	536/2,979 (18%)	0.91 (0.90, 0.93)	82% (79%, 85%) (441/536)	86% (85%, 87%) (2,100/2,443)		28.4 (22.1, 36.5)	-
Female	237/1,661 (14%)	0.94 (0.92, 0.96)	84% (79%, 88%) (199/237)	91% (89%, 92%) (1,290/1,424)		50.4 (34.1, 74.5)	-
Age Group (yrs)							
<40	105/406 (26%)	0.94 (0.91, 0.97)	80% (71%, 87%) (84/105)	94% (91%, 96%) (283/301)		62.9 (32.0, 123.5)	-
40-59	366/1,425 (26%)	0.93 (0.91, 0.95)	84% (80%, 88%) (308/366)	92% (90%, 93%) (969/1,059)		57.2 (40.1, 81.5)	-
60-79	292/2,134 (14%)	0.92 (0.90, 0.94)	83% (78%, 87%) (243/292)	87% (85%, 88%) (1,599/1,842)		32.6 (23.3, 45.6)	-
80+	10/675 (1%)	0.76 (0.62, 0.91)	50% (19%, 81%) (5/10)	81% (78%, 84%) (539/665)		4.3 (1.2, 15.0)	-
Normal ECG							
No	690/2,354 (29%)	0.93 (0.91, 0.94)	86% (83%, 88%) (590/690)	86% (84%, 88%) (1,434/1,664)		36.8 (28.5, 47.4)	-
Yes	83/2,286 (4%)	0.84 (0.79, 0.88)	60% (49%, 71%) (50/83)	89% (87%, 90%) (1,956/2,203)		12.0 (7.6, 19.0)	-
AF/flutter/tachycardia							
No	715/4,319 (17%)	0.92 (0.91, 0.94)	83% (80%, 86%) (593/715)	88% (87%, 89%) (3,162/3,604)		34.8 (27.9, 43.3)	-
Yes	58/321 (18%)	0.89 (0.84, 0.94)	81% (69%, 90%) (47/58)	87% (82%, 91%) (228/263)		27.8 (13.2, 58.7)	-
Ventricular pacing							
No	767/4,530 (17%)	0.92 (0.91, 0.93)	83% (80%, 86%) (637/767)	88% (86%, 89%) (3,295/3,763)		34.5 (27.9, 42.6)	-
Yes	6/110 (5%)	0.84 (0.68, 1.00)	50% (12%, 88%) (3/6)	91% (84%, 96%) (95/104)		10.6 (1.9, 60.1)	-
LBBB							
No	756/4,517 (17%)	0.92 (0.91, 0.93)	83% (80%, 85%) (626/756)	88% (87%, 89%) (3,304/3,761)		34.8 (28.1, 43.1)	-
Yes	17/123 (14%)	0.90 (0.82, 0.98)	82% (57%, 96%) (14/17)	81% (72%, 88%) (86/106)		20.1 (5.3, 76.5)	-
RBBB							
No	732/4,471 (16%)	0.92 (0.91, 0.94)	83% (80%, 86%) (608/732)	88% (87%, 89%) (3,281/3,739)		35.1 (28.3, 43.6)	-
Yes	41/169 (24%)	0.90 (0.83, 0.96)	78% (62%, 89%) (32/41)	85% (78%, 91%) (109/128)		20.4 (8.4, 49.5)	-
LVH criteria							
No	494/4,191 (12%)	0.90 (0.88, 0.91)	76% (72%, 80%) (375/494)	88% (87%, 89%) (3,252/3,697)		23.0 (18.3, 28.9)	-
Yes	279/449 (62%)	0.93 (0.91, 0.96)	95% (92%, 97%) (265/279)	81% (74%, 87%) (138/170)		81.6 (42.2, 158.1)	-
T wave inversions							
No	363/4,051 (9%)	0.88 (0.86, 0.90)	71% (66%, 75%) (256/363)	88% (87%, 89%) (3,259/3,688)		18.2 (14.2, 23.3)	-
Yes	410/589 (70%)	0.91 (0.88, 0.94)	94% (91%, 96%) (384/410)	73% (66%, 80%) (131/179)		40.3 (24.0, 67.6)	-
Pathologic Q waves							
No	700/4,511 (16%)	0.92 (0.91, 0.93)	83% (80%, 85%) (579/700)	88% (87%, 89%) (3,341/3,811)		34.0 (27.3, 42.3)	-
Yes	73/129 (57%)	0.93 (0.89, 0.97)	84% (73%, 91%) (61/73)	88% (76%, 95%) (49/56)		35.6 (13.0, 97.2)	-
Artifact							
No	740/4,461 (17%)	0.93 (0.91, 0.94)	84% (81%, 86%) (619/740)	88% (87%, 89%) (3,269/3,721)		37.0 (29.7, 46.0)	-
Yes	32/178 (18%)	0.82 (0.72, 0.91)	62% (44%, 79%) (20/32)	83% (76%, 89%) (121/146)		8.1 (3.5, 18.6)	-
Overall	773/4,640 (17%)	0.92 (0.91, 0.93)	83% (80%, 85%) (640/773)	88% (87%, 89%) (3,390/3,867)		34.2 (27.7, 42.2)	-

Figure 4 Algorithm performance in age, sex, and electrocardiogram feature subgroups. P-values for within-subgroup comparisons of area under the receiver operating characteristic curves are derived with the DeLong’s test.

cohort self-reported as Asian. Another important finding is the superior diagnostic performance in females when compared with males, a trend previously also observed in the algorithm derivation study. Artificial intelligence electrocardiogram may help address the challenges of delayed diagnosis that potentially leads to worse outcomes of HCM in females.¹⁴

Our validation data offer insights into cohort-specific variations of diagnostic performance. Overall diagnostic performance was high in the combined and in the individual cohorts. The relatively lower sensitivity noted in the Bern and Oxford cohorts compared with the Seoul cohort may be attributed to several reasons. The validation cohorts are distinct from the derivation cohort in terms of geographic origin, clinical practice patterns, and HCM phenotypes. Thus, variation in diagnostic performance is to be expected as with any external validation.¹⁵ Further, specifically in the Bern cohort, patients were older and there was a higher prevalence of other cardiovascular comorbidities such as coronary disease, AF, stroke, and systolic LV dysfunction which

may have confounded AI-ECG performance. Yet, other known or unknown cohort characteristics may weigh more heavily on diagnostic performance than can be easily deduced. Further, we did not re-adjudicate cases and controls for the validity of their HCM and non-HCM status, respectively. Establishing the diagnosis of HCM carries a degree of subjectivity and site-specific diagnostic thresholds for HCM vs. non-HCM hypertrophy, and also, the use of cardiac magnetic resonance imaging for HCM diagnosis may vary. Finally, differences attributable to the different ECG vendors utilized across sites cannot be ruled out.

In a prior investigation of AI-ECG-based detection of HCM, external cross-validation of CNN models among four academic medical centres in the USA and Japan produced AUCs similar to those observed in our study, though notably the model trained in the Japanese cohort demonstrated lower performance when tested in the US cohorts.¹⁶ However, when models were trained with a federated learning approach, overall discrimination improved significantly. In the same study, the AI-ECG




Figure 5 Subgroup performance according to hypertrophic cardiomyopathy characteristics. Results are shown for algorithm performance in each defined subgroup of patients with hypertrophic cardiomyopathy vs. the entire control population. Significant difference in algorithm performance existed only for the apical vs. non-apical hypertrophic cardiomyopathy subgroups. Note that specificity values are identical in the examined subgroups because the control non-hypertrophic cardiomyopathy group is the same across these subgroups.

Table 3 Electrocardiogram characteristics in the hypertrophic cardiomyopathy and control groups

	Patients with HCM (n = 773)	Controls (n = 3867)	Total (n = 4640)	P-value
Normal ECG	83 (10.7%)	2203 (57%)	2286 (49.3%)	<0.001
Atrial fibrillation/flutter/tachycardia	58 (7.5%)	263 (6.8%)	321 (6.9%)	0.48
Ventricular pacing	6 (0.8%)	104 (2.7%)	110 (2.4%)	<0.001
LBBB	17 (2.2%)	106 (2.7%)	123 (2.7%)	0.46
RBBB	41 (5.3%)	128 (3.3%)	169 (3.6%)	0.011
LVH criteria	279 (36.1%)	170 (4.4%)	449 (9.7%)	<0.001
T-wave inversions	410 (53.0%)	179 (4.6%)	589 (12.7%)	<0.001
Pathologic Q waves	73 (9.4%)	56 (1.4%)	129 (2.8%)	<0.001
Tracing artefact	32 (4.1%)	146 (3.8%)	178 (3.8%)	0.61

P-values result from a Wilcoxon rank-sum test (continuous variables) or Fisher’s exact test (categorical variables).

AF, atrial fibrillation; LBBB, left bundle branch block; RBBB, right bundle branch block; LVH, left ventricular hypertrophy.

Normal ECG: sinus rhythm, 50–110 b.p.m., normal intervals, sinus arrhythmia acceptable; bundle branch blocks: complete (QRS >120 ms); LVH per Sokolow–Lyon criteria: S-wave depth in V1 + tallest R-wave height in V5–V6 (whichever is larger) >35 mm; TWIs: inferior or lateral ≥0.1 mV in ≥2 contiguous leads (in those without BBB); pathologic Q waves: ≥1/3 of R-wave or ≥0.3 mV in ≥2 contiguous inferior or lateral leads; artefact: tracing distortion that could interfere with ECG interpretation in the reviewer’s opinion [high-frequency noise, baseline wander, disconnected lead(s), combinations].

HCM model trained by federated learning achieved much higher sensitivities (98%) compared with expert review of ECGs by three different cardiologists (73–81%) in detecting any ECG abnormality.

In a recent explainability analysis using saliency maps, we demonstrated that the ventricular repolarization segment of the ECG is the main driver of our algorithm’s determination of HCM status.¹⁷ In this

validation study, we performed subgroup analyses of ECG features associated with algorithm performance. The presence of ECG artefact had a strong association with false AI-ECG result. In order to follow a most inclusive, real-world approach to ECG interpretation, we did not pre-select or exclude ECGs based on quality. However, it is increasingly recognized that implementation of ECG tracing quality control and potentially refiltering/pre-processing will be important to optimizing performance and reducing the risk of misleading results in the large-scale application of AI-ECG tools.^{18,19} Unsurprisingly, the presence of electrocardiographic LVH was associated with superior algorithm performance, while performance was slightly lower, yet still favourable, with an AUC of 0.84 among completely normal ECGs supporting the notion that this algorithm can raise suspicion and ultimately lead to HCM diagnosis even when no ECG abnormalities are evident. The original derivation work had excluded ECGs with LBBB and ventricular pacing,⁸ yet algorithm performance was not significantly lower among the small samples of ECGs with BBBs or ventricular pacing in this study. However, if applied as a screening tool, HCM with concomitant LBBB or ventricular pacing at the time of diagnosis is seldom if ever seen.

This study included patients undergoing ECG for clinical indications in routine practice. The utility of HCM screening in asymptomatic individuals is yet unknown. In epidemiologic studies, HCM prevalence in the general population is estimated as ~1:200 to 1:500^{20,21} However, only a fraction of those HCM diagnoses come to attention, usually as a result of symptoms, family screening, or incidental findings.² Early diagnosis could reduce HCM-related morbidity and mortality by allowing clinicians to implement disease surveillance, SCD risk stratification, and cascade family screening. Electrocardiogram screening in adolescents and young adults is of particular interest. Hypertrophic cardiomyopathy is one of the most common identifiable causes of SCD in young athletes.^{22,23} However, ECG criteria for HCM detection have shown variable performance and the risk of false positives and subsequent over-testing are concerning.^{24,25} A fully automated, agnostic, and accurate AI tool leveraging the ubiquitous 12-lead ECG without relying on a priori defined ECG features may lead to improved diagnosis of HCM by directing cardiac imaging to subjects with a high AI-ECG-indicated risk. Due to a relatively low HCM prevalence in unselected general populations, the algorithm's positive predictive value (PPV) could be low (<10%) when utilizing binary AI-ECG HCM probability cutpoints geared towards an optimal balance of sensitivity and specificity. However, as shown in our derivation study, the PPV is highly dependent on the operating probability cutpoint.⁸ Raising this probability cutpoint to increase specificity and PPV would be appropriate in a screening application of the algorithm. Reduction of false positive rates could also be achieved by applying the AI-ECG score in conjunction with clinical risk models to identify patients with a higher pre-test probability of HCM.¹² The fusion of deep learning analyses of ECG and echocardiogram data may further augment the accuracy of HCM detection as recently proposed.²⁶

Another potential application of such an algorithm is the diagnostic stratification of patients undergoing ECG for any indication in routine clinical practice, with or without HCM symptoms. A diagnostic approach including AI-ECG and conventional clinical factors may help guide dedicated cardiac imaging to establish or rule out HCM.¹² The concept of treatment response monitoring with AI-ECG in patients receiving targeted HCM therapies was also recently demonstrated in a clinical trial cohort of mavacamten which was approved for obstructive HCM in the USA in 2022.²⁷ Longitudinal monitoring of HCM therapies could be accomplished by a serial AI-ECG analysis of standard ECGs or patient-operated, home-based ECG recording devices. Further, our AI-ECG HCM tool may be useful for screening of first-degree relatives of affected HCM family members, relatives of patients with sudden death of unknown aetiology, and athletes. These groups require further study.

Limitations

Our study has limitations. First, we had a low prevalence of Black patients with HCM in the included cohorts. Generally, Black patients comprise a small portion (<10%) of international HCM cohorts which may be attributable to differences in disease expressivity and genetic architecture of HCM across races, but also due to inequities of care and underrecognition of the disease in Black patients.^{28,29} It is also known that LVH is more prevalent in African-Americans, ECG features of LVH differ by race,^{30,31} and conventional ECG criteria may result in over-referral for suspected cardiac abnormalities in Black athletes.²⁴ The performance of this AI-ECG HCM algorithm in Black patients as well as other underrepresented ethnic/racial subgroups and geographies requires further study. Second, it was not feasible to obtain consecutive control groups inclusive of all patients with non-HCM seen at each site, though it should be emphasized that the control groups were not selected for specific characteristics. Similarly, detailed comorbidity information for the control groups was not available, but the subgroup analyses based on several ECG features presented herein provide insights into algorithm performance across distinct ECG phenotypes. The control groups are representative of patients encountered in routine practice at each institution. From a clinical perspective, this algorithm should ideally be able to distinguish HCM from non-HCM LVH in patients with potential confounding conditions, such as hypertension or aortic stenosis, and this is a focus of further investigation. Finally, the HCM cohorts across the three sites were heterogeneous likely reflecting variations in clinical practice patterns and inherent phenotypic differences across distinct geographic origins, while it should also be noted that we only included patients with available research authorization and digital ECG files which may be partly driving cohort characteristics. Further, a contribution of diagnostic ascertainment bias cannot be fully excluded, particularly due to the retrospective nature of the study. Nevertheless, the algorithm's favourable performance across these heterogeneous cohorts is also suggestive of its robustness.

Conclusion

In this multicentre, international case-control study, we externally validated a previously developed deep learning AI algorithm for the detection of HCM from the standard 12-lead ECG. These data provide insights to guide the effective implementation of this and other AI-ECG algorithms in geographically and racially diverse cohorts. Future prospective efforts are needed to investigate the value of this algorithm in facilitating detection of HCM in the general population and in specific subgroups within healthcare environments.

Funding

Funding support for data management and statistical analyses was provided by the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.

Conflict of interest: P.A.F., Z.I.A., P.A.N., M.J.A., and K.C.S. are co-inventors of the HCM AI-ECG algorithm. Mayo Clinic has licensed the algorithm to Anumana, Inc., with potential for commercialization. K.C.S. has received research funding from Anumana, Inc., for work related to the HCM AI-ECG algorithm (via the institution). M.J.A. is also a consultant for Abbott, Boston Scientific, Bristol Myers Squibb, Daiichi Sankyo, Invitae, LQT Therapeutics, and Medtronic. M.J.A. and Mayo Clinic also have licensing agreements with AliveCor, ARMGO Pharma, Pfizer, and UpToDate. S.W. reports research, travel, or educational grants to the institution from Abbott, Abiomed, Amgen, Astra Zeneca, Bayer, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardinal Health, CardioValve, Corflow Therapeutics, CSL Behring, Daiichi Sankyo, Edwards Lifesciences,

Guerbet, InfraRedx, Janssen-Cilag, Johnson & Johnson, Medtronic, Merck Sharp & Dohm, Miracor Medical, Novartis, Novo Nordisk, Organon, OrPha Suisse, Pfizer, Polares, Regeneron, Sanofi-Aventis, Servier, Sinomed, Terumo, Vifor, and V-Wave. He serves as advisory board member and/or member of the steering/executive group of trials funded by Abbott, Abiomed, Amgen, Astra Zeneca, Bayer, Boston Scientific, Biotronik, Bristol Myers Squibb, Edwards Lifesciences, Janssen, MedAlliance, Medtronic, Novartis, Polares, Recardio, Sinomed, Terumo, V-Wave, and Xeltis with payments to the institution but no personal payments. He is also a member of the steering/executive committee group of several investigator-initiated trials that receive funding by industry without impact on his personal remuneration. B.R. is funded by the BHF Oxford Centre of Research Excellence (RE/18/3/34214). S.N. acknowledges support from the Oxford NIHR Biomedical Research Centre and the Oxford British Heart Foundation Centre of Research Excellence.

Data availability

The individual patient data underlying this article cannot be shared publicly due to intellectual property restrictions. However, certain raw data may be shared on reasonable request to the corresponding author.

References

- Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation* 2020;**6**:e159–e240.
- Maron MS, Hellawell JL, Lucove JC, Farzaneh-Far R, Olivetto I. Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the United States. *Am J Cardiol* 2016;**117**:1651–1654.
- Finocchiaro G, Sheikh N, Biagini E, Papadakis M, Maurizi N, Sinagra G, et al. The electrocardiogram in the diagnosis and management of patients with hypertrophic cardiomyopathy. *Heart Rhythm* 2020;**17**:142–151.
- Drezner JA, Sharma S, Baggish A, Papadakis M, Wilson MG, Prutkin JM, et al. International criteria for electrocardiographic interpretation in athletes: consensus statement. *Br J Sports Med* 2017;**51**:704–731.
- Sharma S, Merghani A, Mont L. Exercise and the heart: the good, the bad, and the ugly. *Eur Heart J* 2015;**36**:1445–1453.
- McLeod CJ, Ackerman MJ, Nishimura RA, Tajik AJ, Gersh BJ, Ommen SR. Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram. *J Am Coll Cardiol* 2009;**54**:229–233.
- Siontis KC, Noseworthy PA, Attia ZI, Friedman PA. Artificial intelligence-enhanced electrocardiography in cardiovascular disease management. *Nat Rev Cardiol* 2021;**18**:465–478.
- Ko WY, Siontis KC, Attia ZI, Carter RE, Kapa S, Ommen SR, et al. Detection of hypertrophic cardiomyopathy using a convolutional neural network-enabled electrocardiogram. *J Am Coll Cardiol* 2020;**75**:722–733.
- Siontis KC, Liu K, Bos JM, Attia ZI, Cohen-Shelly M, Arruda-Olson AM, et al. Detection of hypertrophic cardiomyopathy by an artificial intelligence electrocardiogram in children and adolescents. *Int J Cardiol* 2021;**340**:42–47.
- Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. *Ann Intern Med* 2015;**162**:55–63.
- Authors/Task Force members; Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). *Eur Heart J* 2014;**35**:2733–2779.
- Maanja M, Noseworthy PA, Geske JB, Ackerman MJ, Arruda-Olson AM, Ommen SR, et al. Tandem deep learning and logistic regression models to optimize hypertrophic cardiomyopathy detection in routine clinical practice. *Cardiovasc Digit Health J* 2022;**3**:289–296.
- Siontis GCM, Sweda R, Noseworthy PA, Friedman PA, Siontis KC, Patel CJ. Development and validation pathways of artificial intelligence tools evaluated in randomized clinical trials. *BMJ Health Care Inform* 2021;**28**:e100466.
- Geske JB, Ong KC, Siontis KC, Hebl VB, Ackerman MJ, Hodge DO, et al. Women with hypertrophic cardiomyopathy have worse survival. *Eur Heart J* 2017;**38**:3434–3440.
- Siontis GC, Tzoulaki I, Castaldi PJ, Ioannidis JP. External validation of new risk prediction models is infrequent and reveals worse prognostic discrimination. *J Clin Epidemiol* 2015;**68**:25–34.
- Goto S, Solanki D, John JE, Yagi R, Homiluis M, Ichihara G, et al. Multinational federated learning approach to train ECG and echocardiogram models for hypertrophic cardiomyopathy detection. *Circulation* 2022;**146**:755–769.
- Siontis KC, Suárez AB, Sehrawat O, Ackerman MJ, Attia ZI, Friedman PA, et al. Saliency maps provide insights into artificial intelligence-based electrocardiography models for detecting hypertrophic cardiomyopathy. *J Electrocardiol* 2023;**81**:286–291.
- Li Q, Rajagopalan C, Clifford GD. A machine learning approach to multi-level ECG signal quality classification. *Comput Methods Programs Biomed* 2014;**117**:435–447.
- Attia ZI, Harmon DM, Behr ER, Friedman PA. Application of artificial intelligence to the electrocardiogram. *Eur Heart J* 2021;**42**:4717–4730.
- Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2015;**65**:1249–1254.
- Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary artery risk development in (young) adults. *Circulation* 1995;**92**:785–789.
- Harmon KG, Asif IM, Maleszewski JJ, Owens DS, Prutkin JM, Salerno JC, et al. Incidence, cause, and comparative frequency of sudden cardiac death in national collegiate athletic association athletes: a decade in review. *Circulation* 2015;**132**:10–19.
- Maron BJ, Haas TS, Murphy CJ, Ahluwalia A, Rutten-Ramos S. Incidence and causes of sudden death in U.S. college athletes. *J Am Coll Cardiol* 2014;**63**:1636–1643.
- Sheikh N, Papadakis M, Ghani S, Zaidi A, Gati S, Adami PE, et al. Comparison of electrocardiographic criteria for the detection of cardiac abnormalities in elite black and white athletes. *Circulation* 2014;**129**:1637–1649.
- Pickham D, Zarafshar S, Sani D, Kumar N, Froelicher V. Comparison of three ECG criteria for athlete pre-participation screening. *J Electrocardiol* 2014;**47**:769–774.
- Soto JT, Weston Hughes J, Sanchez PA, Perez M, Ouyang D, Ashley EA. Multimodal deep learning enhances diagnostic precision in left ventricular hypertrophy. *Eur Heart J Digit Health* 2022;**3**:380–389.
- Tison GH, Siontis KC, Abreau S, Attia Z, Agarwal P, Balasubramanyam A, et al. Assessment of disease status and treatment response with artificial intelligence-enhanced electrocardiography in obstructive hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2022;**79**:1032–1034.
- Eberly LA, Day SM, Ashley EA, Jacoby DL, Jefferies JL, Colan SD, et al. Association of race with disease expression and clinical outcomes among patients with hypertrophic cardiomyopathy. *JAMA Cardiol* 2020;**5**:83–91.
- O'Mahony C, Jichi F, Ommen SR, Christiaans I, Arbustini E, Garcia-Pavia P, et al. International external validation study of the 2014 European Society of Cardiology guidelines on sudden cardiac death prevention in hypertrophic cardiomyopathy (EVIDENCE-HCM). *Circulation* 2018;**137**:1015–1023.
- Drazner MH, Dries DL, Peshock RM, Cooper RS, Klassen C, Kazi F, et al. Left ventricular hypertrophy is more prevalent in blacks than whites in the general population: the Dallas Heart study. *Hypertension* 2005;**46**:124–129.
- Jain A, Tandri H, Dalal D, Chahal H, Soliman EZ, Prineas RJ, et al. Diagnostic and prognostic utility of electrocardiography for left ventricular hypertrophy defined by magnetic resonance imaging in relationship to ethnicity: the multi-ethnic study of atherosclerosis (MESA). *Am Heart J* 2010;**159**:652–658.